Phase 2 Study of BAN2401 Fails to Meet 12-month Goal; Proceeds to 18-month Analysis

Phase 2 Study of BAN2401 Fails to Meet 12-month Goal; Proceeds to 18-month Analysis
BAN2401, an investigational anti-amyloid beta antibody therapy for Alzheimer’s disease, has failed to reach the primary endpoint of a Phase 2 clinical trial measured after 12 months of therapy. Study 201 will continue following the predefined protocol, where a comprehensive analysis will be performed after an 18-month treatment period. Final results are expected in the second

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *